das Biovaxys nun das Recht hat das Produkt Papilocare(TM) in den USA zu verkaufen. Das sind immerhin ein prognostzierter Umsatz von 30 mio USD. Wie hoch war nochmal unsere Marktkapitaliserung? :D
HIer nochmals der Orginaltext in english aus den News:
"In a major step toward transitioning to a revenue-generating company, BioVaxys has agreed to have a right of first refusal to market and distribute Papilocare(TM) in the US.
In Procare Health's PALOMA Phase IIb clinical trial, Papilocare(TM) showed consistent and significant efficacy in normalizing cervical cytology at 3 months and at 6 months in the total study population with 50% to 70% of High-Risk HPV clearance at 6 months in six different international studies and more than 600 patients. HPV infection causes 528,000 cases of cervical cancer and 266,000 cervical cancer deaths each year.1 Papilocare(TM) has a CE mark valid for the entire EU, and is currently marketed as a Class IIa medical device in Spain, France, Portugal, Italy, Belgium, Luxembourg, Lithuania, Latvia, Poland, Czech Republic, Hungary, Bulgaria, and Romania. Once the FDA regulatory pathway has been determined for the US, BioVaxys will have a detailed plan in place by 3Q21 to build an appropriate capability to market and support the brand in the US, with BioVaxys providing the funding for such efforts. Preliminary forecasts from Procare anticipate potential US sales of US$30.0 million."
Zurück
